The pharma wholesale and distribution market is estimated to grow at a CAGR of 5.6% in the first half of the forecast period. The market is estimated to reach a revenue of $1.3bn in 2023. In 2017, the branded drugs submarket held 79% of the pharma wholesale and distribution market.
How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 277-page report you will receive 93 tables and 107 figures– all unavailable elsewhere.
The 277-page report provides clear detailed insight into the pharma wholesale and distribution market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
Report Scope
• Global Pharma Wholesale and Distribution Market from 2018-2028
• Forecast of the Global Pharma Wholesale and Distribution market by Category: • Generic Drugs • Branded Drugs • Others
• This report provides individual revenue forecasts to 2028 for these national markets: • US • Germany • France • Italy • Spain • UK • Japan • China • Brazil • India • Russia • RoW
Each National Market is further segmented into generic drugs, branded drugs and others
• Our study discusses the selected leading companies that are the major players in the global pharma and wholesale distribution market: • Alfresa Holdings • AmerisourceBergen • Cardinal Health • McKesson • Medipal • PHOENIX Group • Shanghai Pharma • SINOPHARM • Suzuken • Walgreens Boots Alliance
• This report provides a SWOT and STEP analysis of the pharma wholesale and distribution market.
Visiongain’s study is intended for anyone requiring commercial analyses for the pharma wholesale and distribution market. You find data, trends and predictions.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
1. Report Overview 1.1 Global Pharma Wholesale and Distribution Industry and Market Overview 1.2 Benefits of This Report 1.3 How This Report Delivers 1.4 Questions Answered by This Analytical Report 1.5 Who is This Report For? 1.6 Methodology 1.7 Frequently Asked Questions (FAQ) 1.8 Associated Visiongain Reports 1.9 About Visiongain
2. Introduction to Pharma Wholesale and Distribution 2.1 The Role of Pharmaceutical Wholesalers: The Middlemen of the Pharmaceutical Industry 2.1.1 Full-Line Wholesalers (FLWs) 2.1.2 Short-Line Wholesalers (SLWs) 2.2 The Chain of Distribution: Wholesalers vs. Logistic Service Providers 2.2.1 Secondary Wholesalers 2.2.2 Direct-to-Pharmacy (DTP) Distribution is Becoming More Prevalent 2.2.3 Major Wholesalers: Distribution of a Large Number of Products to Generate High Profits 2.2.4 Distribution from Large to Small Wholesalers: A Lengthy Distribution Chain 2.2.5 Pharmacy Benefit Managers 2.3 Generative Revenue and Profit 2.3.1 Forward Buying to Avoid Price Increases 2.3.2 Fee-for-Service: A Clear Pricing Structure 2.3.2.1 Inventory Management Agreements 2.3.3 Discounts: Incentives for Prompt Payment or Bulk Purchases 2.3.4 Reimbursement and Wholesalers 2.3.5 Clawback: The Recovery of Reimbursement Costs by Governments 2.3.6 Parallel Trade: Different Attitudes in Europe and the US
3. The World Pharmaceutical Wholesale and Distribution Market: 2017-2028 3.1 The World Pharmaceutical Wholesale and Distribution Market in 2017, Restricted by Government Price Reductions and Generic Substitution 3.2 The Pharmaceutical Wholesale and Distribution Industry: World Market Forecast, 2017-2028 3.3 Branded and Generic Drugs: Revenue vs. Profit, 2017-2028 3.3.1 Branded and Generic Drugs: Revenue Generation, 2017 3.3.2 Branded Drugs: Revenue Forecast, 2017-2028 3.3.3 Generic Drugs: Revenue Forecast, 2017-2028
4. Pharmaceutical Wholesale and Distribution Industry: Leading National Markets, 2017-2028 4.1 The Leading National Markets: the US Dominates in 2017 4.2 The Future of the Leading National Markets: Will the US Continue to Dominate the Market? 4.3 The US Pharma Wholesale and Distribution Market 4.3.1 The Budget Control Act and its Effect on the US Wholesale and Distribution Industry 4.3.2 Legislation to Prevent Counterfeit Drugs Can Differ Between States 4.3.3 An Increase in Fee-For-Service Activity 4.3.4 Pharma Wholesale and Distribution Market in the US: Market Forecast, 2017-2028 4.4 The Leading European (EU5) Pharma Wholesale and Distribution Markets 4.4.1 The Difference Between the US and European Markets 4.4.2 State-Funded Healthcare and Reimbursement 4.4.3 EU5: Market Forecast, 2017-2028 4.4.4 Germany: Pharma Wholesale and Distribution Market, 2017 4.4.4.1 Healthcare Reform 4.4.4.2 Germany: Reform of AMNOG Pharmaceutical Rebate Law 4.4.4.3 Germany Pharma Wholesale and Distribution Market Forecast, 2017-2028 4.4.5 France: Pharma Wholesale and Distribution Market, 2017 4.4.5.1 France: Social Security Finance Bill 2015 4.4.5.2 France: Pharma Wholesale and Distribution Market Forecast, 2017-2028 4.4.6 Italy: Pharma Wholesale and Distribution Market, 2017 4.4.6.1 Italy: Pharma Wholesale and Distribution Market Forecast, 2017-2028 4.4.7 Spain: Pharma Wholesale and Distribution Market, 2017 4.4.7.1 Spain: Pharma Wholesale and Distribution Market Forecast, 2017-2028 4.4.8 UK: Pharma Wholesale and Distribution Market, 2017 4.4.8.1 Price Cuts in the UK 4.4.8.2 UK: Pharma Wholesale and Distribution Market Forecast, 2017-2028 4.5 Japan: Pharma Wholesale and Distribution Market, 2017 4.5.1 Drug Pricing and Performing Fees in Japan 4.5.2 Japan: Pharma Wholesale and Distribution Market Forecast, 2017-2028 4.6 China: Pharma Wholesale and Distribution Market, 2017 4.6.1 China: Leading Pharma Wholesale and Distribution Companies, 2017 4.6.2 China: Pharma Wholesale and Distribution Market Forecast, 2017-2028 4.7 Brazil: Pharma and Wholesale Distribution Market, 2017 4.7.1 Drug Price Controls in Brazil 4.7.2 Brazil: Leading Pharma Wholesale and Distribution Companies, 2017 4.7.3 Brazil: Pharma Wholesale and Distribution Market Forecast, 2017-2028 4.8 India: Pharma Wholesale and Distribution Market, 2017 4.8.1 India: Pharma Wholesale and Distribution Market Forecast, 2017-2028 4.9 Russia: Pharma Wholesale and Distribution Market, 2016 4.9.1 Drug Pricing Controls in Russia 4.9.2 Market Trends in Russia 4.9.3 Russia: Pharma Wholesale and Distribution Market Forecast, 2017-2028 4.10 Conclusion
5. Leading Pharma Wholesalers and Distributors In 2016: Current and Future Performance 5.1 The Leading Pharma Wholesalers and Distribution Companies in 2017 5.2 Revenue vs. Profit 5.3 Leading Pharma Wholesale and Distribution Companies: Grouped Forecasts, 2017-2028 5.4 McKesson: The Oldest and Largest Healthcare Services Company in the US 5.4.1 McKesson: Historical Performance, 2011-2016 5.4.2 Future Strategies: Consummate Acquisitions to Complement Existing Business or Expand Businesses 5.4.3 McKesson: Revenue Forecast, 2017-2028 5.5 Cardinal Health: The World’s Third Largest Pharma Wholesaler 5.5.1 Cardinal Health: Historical Performance, 2011-2016 5.5.2 Will CVS Joint Venture and Acquisitions Stimulate Future Growth? 5.5.3 Cardinal Health: Revenue Forecast, 2017-2028 5.6 AmerisourceBergen: Third Largest Global Pharma Wholesaler and Distributor 5.6.1 AmerisourceBergen: Historical Performance, 2016 5.6.2 Will Contracts with Walgreens and Alliance Boots Drive Future Growth? 5.6.3 AmerisourceBergen: Revenue Forecast, 2017-2028 5.7 Walgreens Boots Alliance: The Largest Drugstore Chain in the US and Global Wholesale and Distribution Network 5.7.1 Walgreens Boots Alliance: Historical Performance, 2011-2016 5.7.2 Acquisitions and Future Strategies of Walgreens Boots Alliance 5.7.3 Walgreens Boots Alliance: Revenue Forecast, 2017-2028 5.8 MEDIPAL HOLDINGS CORPORATION: Japan’s Leading Pharmaceutical Wholesaler 5.8.1 MEDIPAL HOLDINGS CORPORATION: Historical Performance, 2011-2016 5.8.2 Future Strategies of MEDIPAL HOLDINGS CORPORATION: Revised Business Portfolio with Diverse Sources of Earnings 5.8.3 MEDIPAL HOLDINGS CORPORATION: Revenue Forecast, 2017-2028 5.9 Phoenix Group: Biggest European Wholesalers 5.9.1 The PHOENIX Group: Historical Performance, 2011-2016 5.9.2 Future Strategies of the PHOENIX Group: Selective Acquisition 5.9.3 The PHOENIX Group: Revenue Forecast, 2017-2028 5.10 SINOPHARM: The Leading Pharmaceutical Wholesaler and Distributor in China 5.10.1 SINOPHARM: Historical Performance, 2011-2016 5.10.2 Future Strategies of SINOPHARM: Provide Comprehensive Services and Wider Business Coverage 5.10.3 SINOPHARM: Revenue Forecast, 2017-2028 5.11 Alfresa Holdings: Second Largest Pharmaceutical Wholesaler and Distributor in Japan 5.11.1 Alfresa Holdings: Historical Performance, 2011-2016 5.11.2 Future Strategy of Alfresa Holdings: To Focus on Expanding Business Fields and Increasing Footprint 5.11.3 Alfresa Holdings: Revenue Forecast, 2017-2028 5.12 SUZUKEN CO., LTD: The First Nationwide Wholesaler of Japan 5.12.1 SUZUKEN CO. LTD: Historical Performance, 2011-2016 5.12.2 Future Strategies of SUZUKEN CO., LTD: Five Growth Initiatives and Special Focus on Diabetes Field 5.12.3 SUZUKEN CO., LTD: Revenue Forecast, 2017-2028 5.13 Shanghai Pharmaceuticals Holding: China’s Second Largest Wholesaler 5.13.1 Shanghai Pharmaceuticals Holding: Historical Performance, 2011-2016 5.13.2 Future Strategies of Shanghai Pharma: Expansion of Three Leading Regions in China 5.13.3 Shanghai Pharma: Revenue Forecast, 2017-2028
6. Qualitative Analysis of the Pharma Wholesale and Distribution Market 6.1 The Strengths and Weaknesses of the Pharma Wholesale and Distribution Market, 2017 6.1.1 The Insatiable Demand for Drugs: A Recession Proof Industry? 6.1.2 Wholesalers Do More than Deliver Drugs 6.1.2.1 Pre-Wholesaling: More Prevalent in Europe 6.1.2.2 Through Pre-Financing, Full-Line Wholesalers Finance the Entire Medicines Market 6.1.3 Large Companies Dominate the Market 6.1.4 Despite High Revenues, Profit Margins Are Low 6.1.5 Government-Induced Drug Price Pressures Restrict Profits 6.1.6 The Problem of Counterfeit Drugs 6.2 The Opportunities and Threats of the Pharma Wholesale and Distribution Market, 2017-2028 6.2.1 The Demand for Pharmaceuticals is Increasing 6.2.2 The Increasing Use of Specialty Drugs Will Drive Growth 6.2.3 The Increasing Use of Generic Drugs Will Limit Revenue but Drive Profit Generation 6.2.4 The Promotion of Drug Therapy in the US 6.2.5 Globalisation: The Major National Markets are Dominated by Few Companies 6.2.6 Increased Adoption of the DTP Distribution Model 6.2.6.1 DTP in Europe: The First Place the Scheme Has Taken Hold 6.2.6.2 DTP in the UK Since 1991 6.2.6.3 DTP in Poland: The Second European Country To Adopt the DTP Model 6.2.6.4 Further Expansion of the DTP Model 6.2.7 The Threat of Healthcare Budget Cuts 6.2.7.1 Healthcare Budget Cuts in Germany 6.2.7.2 Healthcare Budget Cuts in France 6.2.7.3 Healthcare Budget Cuts in Italy 6.2.7.4 Healthcare Budget Cuts in Spain 6.2.7.5 Healthcare Budget Cuts in the UK 6.2.8 Do Large Pharmacy Chains Pose a Threat? 6.2.8.1 Case Study: Walmart and the $4 Prescription Scheme 6.2.8.2 Vertical Integration of Wholesalers: A Response to the Threat of Pharmacy Chains 6.2.9 Does the Diversion and Re-Importation of Medicines Pose a Threat to the Industry? 6.2.10 The Threat of Industry Consolidation 6.3 Social, Technological, Economic and Political Factors Influencing the Market, 2017-2028 (STEP Analysis) 6.3.1 Political Factor: The Impact of Recent Regulatory Changes in the EU 6.3.2 Political Factor: Combating Counterfeit Medicines 6.3.2.1 The US and E-Pedigree: Becoming Law in California 6.3.2.2 European Pedigree Legislation 6.3.2.3 Anti-Counterfeiting Strategies in Other Markets: The Chinese Government is Attempting to Address the Challenge 6.3.2.4 Serialisation for Wholesalers: Opportunity or a Challenge?
7. Conclusions 7.1 The Future of the Pharma Wholesale and Distribution Market 7.2 The Leading National Pharma Wholesale and Distribution Markets 7.3 The Leading Companies in the Pharma Wholesale and Distribution Industry 7.4 Trends in the Pharma Wholesale and Distribution Industry 7.4.1 Generics Will Threaten Revenue 7.4.2 Manufacturers Will Deliver More Drugs Directly 7.4.3 There Will Be Greater Demand for Specialty Medicines 7.4.4 Consolidation Will Drive Growth 7.4.5 Anti-Counterfeiting Demands Will Add to Wholesalers’ Costs
Appendices Associated Visiongain Reports Visiongain Report Sales Order Form About Visiongain Visiongain Report Evaluation Form
List of Tables Table 2.1 Use of DTP Model in the UK, 2007-2012 Table 3.1 Pharmaceutical Wholesale and Distribution: World Market Forecast ($bn), AGR (%), CAGR (%), 2017-2028 Table 3.2 Pharmaceutical Wholesale and Distribution: Branded Drugs, Generic Drugs and Others, Revenue ($bn) Forecasts, AGR (%), CAGR (%) and Market Shares (%), 2017-2028 Table 3.3 Wholesale and Distribution of Branded Drugs: Revenue ($bn) and Market Share (%) Forecast, 2017-2028 Table 3.4 Wholesale and Distribution of Generic Drugs: Revenue ($bn) and Market Share (%) Forecast, 2017-2028 Table 4.1 Pharma Wholesale & Distribution Leading National Markets: Revenues ($bn) and Market Share (%), 2017 Table 4.2 Pharma Wholesale & Distribution Leading National Markets: Revenue ($bn) Forecasts, AGR (%) and CAGR (%), 2017-2028 Table 4.3 US Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2017-2028 Table 4.4 Us Pharma Wholesale & Distribution Market by Drugs Category: Revenue ($bn) Forecast, AGR (%) And CAGR (%), 2017-2028 Table 4.5 Price Controls in Europe, 2016 Table 4.6 EU5 Pharma Wholesale & Distribution Market: Revenue ($bn) Forecasts, AGR (%) and CAGR (%), 2017-2028 Table 4.7 German Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2017-2028 Table 4.8 German Pharma Wholesale & Distribution Market by Drugs Category: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2017-2028 Table 4.9 French Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2017-2028 Table 4.10 French Pharma Wholesale & Distribution Market by Drugs Category: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2017-2028 Table 4.11 Italian Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2017-2028 Table 4.12 Italian Pharma Wholesale & Distribution Market by Drugs Category: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2017-2028 Table 4.13 Spanish Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2017-2028 Table 4.14 Spanish Pharma Wholesale & Distribution Market by Drugs Category: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2017-2028 Table 4.15 UK Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2017-2028 Table 4.16 UK Pharma Wholesale & Distribution Market by Drugs Category: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2017-2028 Table 4.17 Percentage of The Population Ages 60+ In the Us, Europe, Japan, China and India, 2015 And 2030 Table 4.18 Japanese Pharmaceutical Wholesale and Distribution Market: Drug Price Revision Growth (%), 2007-2017 Table 4.19 Japanese Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2017-2028 Table 4.20 Japanese Pharma Wholesale & Distribution Market by Drugs Category: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2017-2028 Table 4.21 Chinese Pharma Wholesale & Distribution: Revenue ($bn) And Market Shares (%) of Leading Companies, 2017 Table 4.22 Chinese Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2017-2028 Table 4.23 Chinese Pharma Wholesale & Distribution Market by Drugs Category: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2017-2028 Table 4.24 Brazilian Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2017-2028 Table 4.25 Brazilian Pharma Wholesale & Distribution Market by Drugs Category: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2017-2028 Table 4.26 Indian Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2017-2028 Table 4.27 Indian Pharma Wholesale & Distribution Market by Drugs Category: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2017-2028 Table 4.28 Russian Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2017-2028 Table 4.29 Russian Pharma Wholesale & Distribution Market: Revenue ($Bn) Forecast, AGR (%) and CAGR (%), 2017-2028 Table 5.1 Leading Companies in The Pharmaceutical Wholesale and Distribution Market: Revenues ($bn) and Market Shares (%), 2017 Table 5.2 Leading Pharmaceutical Wholesale and Distribution Companies: Revenue Forecasts ($bn), AGR (%) and CAGR (%), 2017-2028 Table 5.3 Leading Pharmaceutical Wholesale and Distribution Companies: Market Shares (%) for 2017, 2022 And 2028 Table 5.4 Mckesson, Distribution Solutions: Services and Customers, 2017 Table 5.5 Mckesson, Technology Solutions: Services and Customers, 2017 Table 5.6 Mckesson: Historical Revenue ($bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit ($bn), Gross Profit AGR (%) and Gross Profit CAGR (%), 2011-2016 Table 5.7 Mckesson: Revenue ($bn), Revenue Share (%) and AGR (%) Breakdown by Business Segment, 2016-2017 Table 5.8 Mckesson: Gross Profit ($bn), Gross Profit Share (%) and AGR (%) Breakdown by Business Segment, 2016-2017 Table 5.9 Acquisitions by Mckesson, 2007-2018 Table 5.10 Mckesson: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2017-2028 Table 5.11 Cardinal Health: Historical Revenue ($bn), Revenue AGR (%), Revenue CAGR (%), Operating Earnings ($bn), AGR (%) and CAGR (%), 2010-2015 Table 5.12 Cardinal Health: Revenue ($bn), Revenue Share (%) and AGR (%) Breakdown by Business Segment, 2016-2017 Table 5.13 Cardinal Health: Operating Earnings ($bn) and Annual Growth (%) Breakdown by Business Segment, 2016-2017 Table 5.14 Cardinal Health: Revenue ($bn) And Revenue Share (%) Breakdown by Customer, 2017 Table 5.15 Selected Acquisitions by Cardinal Health and Their Line of Business, 2007-2018 Table 5.16 Cardinal Health: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2017-2028 Table 5.17 Amerisourcebergen: Historical Revenue ($bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit ($bn), Gross Profit AGR (%) and Gross Profit CAGR (%), 2011-2016 Table 5.18 Amerisourcebergen: Revenue ($bn), Revenue Share (%) and AGR (%) Breakdown by Business Segment, 2016-2017 Table 5.19 Amerisourcebergen: Gross Profit ($bn), Gross Profit Share (%) and AGR (%) Breakdown by Business Segment, 2016-2017 Table 5.20 Amerisourcebergen: Revenue ($bn) and Revenue Share (%) Breakdown by Customer, 2017 Table 5.21 Acquisitions by Amerisourcebergen and Their Line of Business, 2007-2018 Table 5.22 Amerisourcebergen: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2017-2028 Table 5.23 Walgreens Boots Alliance: Revenue ($bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit ($bn), Gross Profit AGR (%) and Gross Profit CAGR (%), 2011-2016 Table 5.24 Walgreens Boots Alliance: Pharmaceutical Wholesale Revenue ($bn), AGR (%), and CAGR (%) Forecast, 2017-2028 Table 5.25 Medipal Holdings: Consolidated Subsidiary Companies, 2017 Table 5.26 Medipal Holdings: Historical Revenue (¥bn, $bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit (¥bn, $bn), Gross Profit AGR (%) and Gross Profit CAGR (%), 2011-2016 Table 5.27 Medipal Holdings: Revenue (¥bn, $bn) and Revenue Share (%) and AGR (%) Breakdown by Business Segment, 2016-2017 Table 5.28 Medipal Holdings: Operating Income ($bn, ¥bn), Operating Income Share (%) and AGR (%) Breakdown by Business Segment, 2016-2017 Table 5.29 Medipal Holdings: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2017-2028 Table 5.30 Phoenix Group: Subsidiary Companies, 2017 Table 5.31 Phoenix Group: Historical Revenue (€bn, $bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit (€bn, $bn), Gross Profit AGR (%) and Gross Profit CAGR (%), 2011-2016 Table 5.32 Phoenix Group: Revenue (€bn, $bn), Revenue Share (%) Breakdown by Region, 2017 Table 5.33 Phoenix Group: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2017-2028 Table 5.34 Sinopharm Group: Historical Revenue (RMBbn, $bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit (RMBbn, $bn), Gross Profit AGR (%) and Gross Profit CAGR (%), 2011-2016 Table 5.35 Sinopharm Group: Revenue (RMBbn, $bn) and Revenue Share (%) and AGR (%) Breakdown by Business Segment, 2016-2017 Table 5.36 Sinopharm Group: Operating Profit (RMBbn, $bn), Operating Profit Share (%) and AGR (%) Breakdown by Business Segment, 2015-2016 Table 5.37 Sinopharm Group: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2017-2028 Table 5.38 Alfresa Holdings: List of Significant Subsidiaries and Affiliates, 2017 Table 5.39 Alfresa Holdings: Historical Revenue (¥bn, $bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit (¥bn, $bn), Gross Profit AGR (%) and Gross Profit CAGR (%), 2011-2016 Table 5.40 Alfresa Holdings: Business Strategies, 2013-2017 Table 5.41 Alfresa Holdings: Revenue (¥bn, $bn), Revenue Share (%) and AGR (%) Breakdown by Business Segment, 2016-2017 Table 5.42 Alfresa Holdings: Gross Profit (¥bn, $bn), Gross Profit Share (%) and AGR (%) Breakdown by Business Segment, 2016-2017 Table 5.43 Alfresa Holdings: Challenges for the 16-18 Mid-Term Management Plan - Break Through to Tomorrow, 2016 Table 5.44 Alfresa Holdings: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2017-2028 Table 5.45 Suzuken: Historical Revenue (¥bn, $bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit (¥bn, $bn), Gross Profit AGR (%) and Gross Profit CAGR (%), 2011-2016 Table 5.46 Suzuken: Revenue (¥bn, $bn), Revenue Share (%) and AGR (%) Breakdown by Business Segment, 2015-2016 Table 5.47 Suzuken: Operating Income (¥bn, $bn), Operating Income Share (%) and AGR (%) Breakdown by Business Segment, 2015-2016 Table 5.48 Suzuken: Revenue (¥bn, $bn), Revenue Share (%) Breakdown for Pharmaceuticals Distribution Segment by Region, 2014 Table 5.49 Suzuken: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2017-2028 Table 5.50 Shanghai Pharmaceuticals Holding: Historical Revenue (RMBbn, $bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit (RMBbn, $bn), Gross Profit AGR (%) and Gross Profit CAGR (%), 2011-2016 Table 5.51 Shanghai Pharmaceuticals Holding: Revenue (RMBbn, $bn), Revenue Share (%) and AGR (%) Breakdown by Business Segment, 2015-2016 Table 5.52 Shanghai Pharmaceuticals Holding: Operating Profit (RMBbn, $bn), Operating Profit Share (%) and AGR (%) Breakdown by Business Segment, 2015-2016 Table 5.53 Shanghai Pharmaceuticals Holding: Distribution Revenue (RMBbn, $bn), Distribution Revenue Share (%) Breakdown by Region, 2016 Table 5.54 Shanghai Pharmaceuticals Holding: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2017-2028 Table 6.1 The Pharmaceutical W&D Market: Strengths and Weaknesses, 2017 Table 6.2 The Pharmaceutical W&D Market: Opportunities and Threats, 2017-2028 Table 6.3 Strengths and Weaknesses of The DTP Distribution Model, 2017 Table 6.4 ITR Ratings and Corresponding Reimbursement Rates, 2017 Table 6.5 Social, Technological, Economic and Political Factors Influencing the Pharmaceutical Wholesale and Distribution Market (Step Analysis), 2017-2028
List of Figures Figure 2.1 Routes of Drug Distribution, 2017 Figure 3.1 The Global Pharmaceutical Wholesale and Distribution Market: Drivers and Restraints, 2017 Figure 3.2 Pharmaceutical Wholesale and Distribution: World Market Forecast ($Bn), 2017-2028 Figure 3.3 Branded Drugs, Generic Drugs and Others: Market Shares (%), 2017 Figure 3.4 Pharmaceutical Wholesale and Distribution: World Market Forecast ($Bn) By Category, 2017-2028 Figure 3.5 Branded Drugs, Generic Drugs and Others: Market Shares (%), 2023 Figure 3.6 Branded Drugs, Generic Drugs and Others: Market Shares (%), 2028 Figure 3.7 Wholesale and Distribution of Branded Drugs, Generic Drugs and Others: Revenue Forecasts ($bn), 2017-2028 Figure 3.8 Wholesale and Distribution of Branded Drugs: Revenue ($bn) Forecast, 2017-2028 Figure 3.9 Wholesale and Distribution of Generic Drugs: Revenue ($bn) Forecast, 2017-2028 Figure 4.1 Pharma Wholesale & Distribution Leading National Markets: Shares (%), 2017 Figure 4.2 Pharma Wholesale & Distribution Leading National Markets: Shares (%), 2023 Figure 4.3 Pharma Wholesale & Distribution Leading National Markets: Shares (%), 2028 Figure 4.4 Market Share (%) Breakdown of The Us Market: The 3 Leading Companies, 2017 Figure 4.5 US Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, 2017-2028 Figure 4.6 US Pharma Wholesale & Distribution Market by Drugs Category: Revenue ($bn) Forecast, 2017-2028 Figure 4.7 US Pharma Wholesale & Distribution Market: Drivers and Restraints, 2017 Figure 4.8 EU5 Pharma Wholesale & Distribution Market Shares (%), 2017, 2023 And 2028 Figure 4.9 EU5 Pharma Wholesale & Distribution Market: Revenue ($bn) Forecasts, 2017-2028 Figure 4.10 EU Pharma Wholesale & Distribution Market: Drivers and Restraints, 2017 Figure 4.11 German Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, 2017-2028 Figure 4.12 German Pharma Wholesale & Distribution Market by Drugs Category: Revenue ($Bn) Forecast, 2017-2028 Figure 4.13 German Pharma Wholesale & Distribution Market: Drivers and Restraints, 2017 Figure 4.14 French Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, 2017-2028 Figure 4.15 French Pharma Wholesale & Distribution Market by Drugs Category: Revenue ($bn) Forecast, 2017-2028 Figure 4.16 French Pharma Wholesale & Distribution Market: Drivers and Restraints, 2017 Figure 4.17 Italian Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, 2017-2028 Figure 4.18 Italian Pharma Wholesale & Distribution Market by Drugs Category: Revenue ($bn) Forecast, 2017-2028 Figure 4.19 Italian Pharma Wholesale & Distribution Market: Drivers and Restraints, 2017 Figure 4.20 Spanish Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, 2017-2028 Figure 4.21 Spanish Pharma Wholesale & Distribution Market by Drugs Category: Revenue ($bn) Forecast, 2017-2028 Figure 4.22 Spanish Pharma Wholesale & Distribution Market: Drivers and Restraints, 2017 Figure 4.23 UK Pharma Wholesale & Distribution Market: Revenue ($bn), 2017-2028 Figure 4.24 UK Pharma Wholesale & Distribution Market by Drugs Category: Revenue ($bn) Forecast, 2017-2028 Figure 4.25 UK Pharma Wholesale & Distribution Market: Drivers and Restraints, 2017 Figure 4.26 Percentage of The Population Ages 65+ in the Us, Europe, Japan, China and India, 2015 And 2030 Figure 4.27 Japanese Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, 2017-2028 Figure 4.28 Japanese Pharma Wholesale & Distribution Market by Drugs Category: Revenue ($bn) Forecast, 2017-2028 Figure 4.29 Japanese Pharma Wholesale & Distribution Market: Drivers and Restraints, 2017 Figure 4.30 Chinese Pharma Wholesale & Distribution: Market Shares (%) of Leading Companies, 2017 Figure 4.31 Chinese Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, 2017-2028 Figure 4.32 Chinese Pharma Wholesale & Distribution Market by Drugs Category: Revenue ($bn) Forecast, 2017-2028 Figure 4.33 Chinese Pharma Wholesale & Distribution Market: Drivers and Restraints, 2017 Figure 4.34 Brazilian Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, 2017-2028 Figure 4.35 Brazilian Pharma Wholesale & Distribution Market by Drugs Category: Revenue ($bn) Forecast, 2017-2028 Figure 4.36 Brazilian Pharma Wholesale & Distribution Market: Drivers and Restraints, 2017 Figure 4.37 Pharma Wholesale & Distribution Model in India, 2017 Figure 4.38 Indian Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, 2017-2028 Figure 4.39 Indian Pharma Wholesale & Distribution Market by Drugs Category: Revenue ($bn) Forecast, 2017-2028 Figure 4.40 Indian Pharma Wholesale & Distribution Market: Drivers and Restraints, 2017 Figure 4.41 Russian Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, 2017-2028 Figure 4.42 Russian Pharma Wholesale & Distribution Market by Drugs Category: Revenue ($Bn) Forecast, 2017-2028 Figure 4.43 Russian Pharma Wholesale & Distribution Market: Drivers and Restraints, 2017 Figure 5.1 Leading Pharmaceutical Wholesale and Distribution Companies: Market Shares (%), 2017 Figure 5.2 Leading Pharmaceutical Wholesale and Distribution Companies: Market Shares (%), 2023 Figure 5.3 Leading Pharmaceutical Wholesale and Distribution Companies: Market Shares (%), 2028 Figure 5.4 Leading Pharmaceutical W&D Companies: Drivers and Restraints, 2017 Figure 5.5 Mckesson: Historical Revenue ($bn), Revenue AGR (%), Gross Profit ($bn) And Gross Profit AGR (%), 2011-2016 Figure 5.6 Mckesson: Revenue Share (%) Breakdown by Business Segment, 2016 Figure 5.7 Mckesson: Revenue Share (%) Breakdown by Business Segment, 2017 Figure 5.8 Mckesson: Revenue ($bn) Forecast, 2017-2028 Figure 5.9 Mckesson: Drivers and Restraints, 2017 Figure 5.10 Cardinal Health: Historical Revenue ($bn), Revenue AGR (%), Operating Earnings ($bn) and Operating Earnings AGR (%), 2011-2016 Figure 5.11 Cardinal Health: Revenue Share (%) Breakdown by Business Segment, 2017 Figure 5.12 Cardinal Health: Revenue Share (%) Breakdown by Customer, 2017 Figure 5.13 Cardinal Health: Revenue ($bn) Forecast, 2017-2028 Figure 5.14 Cardinal Health: Drivers and Restraints, 2017-2028 Figure 5.15 Amerisourcebergen: Historical Revenue ($bn), Revenue AGR (%), Gross Profit ($bn) and Gross Profit AGR (%), 2011-2016 Figure 5.16 Amerisourcebergen: Revenue Share (%) Breakdown by Business Segment, 2017 Figure 5.17 Amerisourcebergen: Revenue ($bn) Breakdown by Customer, 2017 Figure 5.18 Amerisourcebergen: Revenue ($bn) Forecast, 2017-2028 Figure 5.19 Amerisourcebergen: Drivers and Restraints, 2017 Figure 5.20 Walgreens Boots Alliance: Revenue ($bn), Revenue AGR (%), Gross Profit ($bn) and Gross Profit AGR (%), 2011-2016 Figure 5.21 Walgreens Boots Alliance: Revenue ($bn) Forecast, 2017-2028 Figure 5.22 Alliance Boots: Drivers and Restraints, 2017-2028 Figure 5.23 Medipal Holdings: Historical Revenue (¥bn), Revenue AGR (%), Gross Profit (¥bn) and Gross Profit AGR (%), 2011-2016 Figure 5.24 Medipal Holdings: Revenue Share (%) Breakdown by Business Segment, 2016 Figure 5.25 Medipal Holdings: Operating Income Share (%) Breakdown by Business Segment, 2017 Figure 5.26 Medipal Holdings: Revenue ($bn) Forecast, 2017-2028 Figure 5.27 Medipal Holdings: Drivers and Restraints, 2017 Figure 5.28 Phoenix Group: Historical Revenue (€bn), Revenue AGR (%), Gross Profit (€bn) and Gross Profit AGR (%), 2011-2016 Figure 5.29 Phoenix Group: Revenue Share (%) Breakdown by Region, 2014 Figure 5.30 Phoenix Group: Revenue ($bn) Forecast, 2017-2028 Figure 5.31 Phoenix Group Drivers and Restraints, 2017 Figure 5.32 Sinopharm Group: Historical Revenue (RMBbn), Revenue AGR (%), Gross Profit (RMBbn) and Gross Profit AGR (%), 2011-2016 Figure 5.33 Sinopharm Group: Revenue ($bn) Forecast, 2017-2028 Figure 5.34 Sinopharm Group: Drivers and Restraints, 2017 Figure 5.35 Alfresa Holdings: Historical Revenue (¥bn), Revenue AGR (%), Gross Profit (¥bn), Gross Profit AGR (%), 2011-2016 Figure 5.36 Alfresa Holdings: Revenue Share (%) Breakdown by Business Segment, 2016 Figure 5.37 Alfresa Holdings: Gross Profit Share (%) Breakdown by Business Segment, 2017 Figure 5.38 Alfresa Holdings: Revenue ($bn) Forecast, 2017-2028 Figure 5.39 Alfresa Holdings: Drivers and Restraints, 2017 Figure 5.40 Suzuken: Historical Revenue (¥bn), Revenue AGR (%), Gross Profit (¥bn) and Gross Profit AGR (%), 2011-2016 Figure 5.41 Suzuken: Revenue Share (%) Breakdown by Business Segment, 2015 Figure 5.42 Suzuken: Operating Income Share (%) Breakdown by Business Segment, 2016 Figure 5.43 Suzuken: Revenue Share (%) Breakdown by Region in Japan, 2014 Figure 5.44 Suzuken: Revenue ($bn) Forecast, 2017-2028 Figure 5.45 Suzuken: Drivers and Restraints, 2017 Figure 5.46 Shanghai Pharmaceuticals Holding: Historical Revenue (RMBbn), Revenue AGR (%), Gross Profit (RMBbn) and Gross Profit AGR (%), 2011-2016 Figure 5.47 Shanghai Pharmaceuticals Holding: Revenue Share (%) Breakdown by Business Segment, 2016 Figure 5.48 Shanghai Pharmaceuticals Holding: Revenue Share (%) Breakdown by Region, 2016 Figure 5.49 Shanghai Pharmaceuticals Holding: Revenue ($bn) Forecast, 2017-2028 Figure 5.50 Shanghai Pharmaceuticals Holding: Drivers and Restraints, 2017 Figure 6.1 Comparison of The Wholesale and DTP Routes of Distribution, 2017 Figure 7.1 Pharmaceutical Wholesale and Distribution: Global Market Forecasts ($Bn) By Submarket, 2017-2028 Figure 7.2 Leading National Pharmaceutical Wholesale and Distribution Markets: Revenue Projections ($Bn), 2017, 2022 And 2028 Figure 7.3 Leading Pharmaceutical Wholesale and Distribution Companies: Revenue ($Bn) Projections 2017, 2022 And 2028
36.6 AAH Pharmaceuticals AccessClosure Acofarma (Asociación Cooperativas Farmacéuticas) ADG Apotheken-Dienstleistungsgesellschaft mbH Admenta Alfresa Fine Chemical Corporation Alfresa Holdings Alliance Boots Alliance Healthcare Alliance Santé Alliance UniChem AmeriSource Health AmerisourceBergen AmerisourceBergen Canada AmerisourceBergen Drug Corporation (ABDC) AmerisourceBergen specialty Group (ABSG) Apollo Medical Holdings ASTEC Co., Ltd. ASTIS Co., Ltd. Athos Farma ATOL CO., LTD. Azwell Bayer BENU Apotheek Bergen Brunswig Biologics Inc Boots Group Bristol-Myers Squibb Brocacef Groep NV Brocacef Holding Bundesverband des Pharmazeutischen Grosshandel Cardinal Health Caremark Rx Celesio AG CERP Bretagne Nord CERP Rhin Rhone Mediterranee CERP Rouen Chiyaku Co Chuounyu Co., Ltd. Cloumed Corporation Cofares Comifar Cordis CoverMyMeds CoverMyMeds LLC CVS Caremark CVS Corporation CVS Health Corporation Cystic Fibrosis Foundation Pharmacy, LLC Daiichi Sankyo Propharma Co. Dong Ying (Jiangsu) Pharmaceuticals Co., Ltd. Drogarias Tamoio Drug Trading Company Ltd Dutch ACM Emart Company ENSHU YAKUHIN CO., LTD. Ethicon EVERLTH AGROTECH Co., Ltd. EVERLTH Co., Ltd. Farcopa Distribuzione Fukujin Co. Good Service Co Guangzhou Pharmaceutical Company Ltd. Guangzhou Pharmaceuticals Corporation Harvard Drug Hedef Alliance Hefame HEISEI YAKUHIN CO., LTD. IZUTSU KURAYA SANSEIDO Inc. IZUTSU PHARMACEUTICAL CO. LTD. Japanese Pharmaceutical Wholesalers Association Jingu Yakuhin Co., Ltd. Johnson & Johnson Katren Kenzmedico Co., Ltd. Kerr Drug KOBASHOU. CO., LTD. KURAYA SANSEIDO Inc Life Medicom Co., Ltd. Lloyds Pharmacy MARUZEN YAKUHIN CO., LTD. McKesson McQueary Brothers of Springfield Medical Specialties Distributors MEDICEO CORPORATION Medicine Shoppe Canada Inc. MEDIE Co., Ltd. MEDIPAL HOLDINGS CORPORATION Mediq Apotheken Nederland B.V. Medtronic Meinan Distribution Center Metro Medical Supply Inc Mitsubishi MM CORPORATION MP AGRO CO., LTD. MVC CO., LTD MWI Veterinary Supply, Inc. Nadro Nakano Yakuhin Co., Ltd. National Health Service (NHS) National Pharmaceutical Pricing Authority (NPPA) Nihon Apoch Co. Novo Nordisk Novodata Zrt. Numark OCP Oncology Therapeutics Oncoprod OptumRx P.J.D. Network PALTAC CORPORATION Paltac Corporation Paltac Corporation PALTAC KS CORPORATION Panpharma Pfercos Co., Ltd. Pfizer PharMEDium Polska Grupa Farmaceutyczna Profarma Prosper Protek PSC Co, Ltd. PSS World Medical Inc. Ratiopharm RDC Kanto5 Red Oak Sourcing Red Oak, LLC Rexall Health Rite Aid Corporation Rosta RxCrossroads S. D.Collabo Co.,Ltd. S.D.Logi CO., Ltd. Sakurai Tsusho Corporation Sanacorp Sandoz Sanki Corporation Sanki MediHeart Limited Sanki Wellbe Sanki Wellbe Co., Ltd. Sannova Sanwa Kagaku Kenkyusho Co., Ltd. S-Care Mate Co., Ltd. Sciclone Trade SEIWA SANGYO CO Shanghai Fosun Pharmaceutical Shanghai Pharma Zhenjiang Co., Ltd. Shanghai Pharmaceutical Holdings Shinohara Chemicals Shinsegai Group Shoyaku Co., Ltd. SIA International Sincamesp SINOPHARM S-mile, Inc Sonexus Health SPH Jiangxi Shangrao Pharmaceutical Co., Ltd. SPH Keyuan Xinhai Pharmaceutical Hebei Co., Ltd. SPH Keyuan Xinhai Pharmaceutical Heilongjiang Co., Ltd. SPLine Corporation SUZUKEN Suzuken Co., Ltd. Suzuken Iwate Co., Ltd. Suzuken Medical Instruments Co, Ltd Suzuken Okinawa Yakuhin Co., Ltd. The PHOENIX Group Toho Holdings Tokiwa Yakuhin Co Torfarm Tradex International TS Alfresa Corporation UniChem US Oncology Holdings, Inc. USHIODA KURAYA SANSEIDO Inc. USHIODA SANGOKUDO YAKUHIN CO., LTD. Vaccine Safe Co Vantage Oncology Victoria Merger Sub, Inc. Vitaco Holdings Walgreen Walgreens Boots Alliance World Courier Group Inc. Wyeth Pharmaceuticals YAMAHIRO KURAYA SANSEIDO Inc. Yunnan Pharmaceutical Co., Ltd. Zuellig Pharma
Download sample pages
Complete the form below to download your free sample pages for Pharma Wholesale and Distribution Market Forecasts 2018-2028
Contract manufacturing represents the largest sector of the pharma outsourcing industry. Pharmaceutical companies have sought to take advantage of the...
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.” Dr Luz Chapa Azuella, Mexico
The global Bioreactors market was estimated to be valued at US$ 9,9770.0 million in 2023 and is expected to register a CAGR of 12.2% from 2023 to 2033.
Visiongain Publishes 3D Printing for Healthcare Market Report 2023-2033
The global 3D Printing for Healthcare market was valued at US$2,970.7 million in 2022 and is projected to grow at a CAGR of 23.6% during the forecast period 2023-2033.
Visiongain Publishes Clinical Trial Supply and Logistics Market for Pharma 2023-2033
The global Clinical Trial Supply and Logistics for Pharma market is valued at US$13.8 billion in 2023 and is projected to grow at a CAGR of 8.4% during the forecast period 2023-2033.
The global Anti-infective Vaccines market is valued at US$48,360.4 million in 2023 and is projected to grow at a CAGR of 6.6% during the forecast period 2023-2033.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
